Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences' stock price has significantly declined over the past year. Key events impacting the stock price include the announcement of a patent issuance on December 29, 2025, the appointment of David Johnson as Chairman of ENvue Medical on December 15, 2025, the exercise of warrants for $3.1 million in gross proceeds on December 11, 2025, and a Notice of Allowance for its EVM301 Series of drug candidates on December 9, 2025, which led to a stock increase. Additionally, a stock split occurred on October 28, 2025, and the company received a delisting notice from Nasdaq on October 23, 2025. The last reported earnings were released on September 29, 2025, and the company received FDA feedback on its EB-003 IND submission on September 16, 2025. Second-quarter 2025 financial results and a business update were announced on August 14, 2025.

As a biotechnology company in early development stages, Enveric Biosciences does not exhibit traditional demand seasonality. Demand is driven by research milestones, clinical trial results, regulatory approvals, and funding cycles rather than seasonal consumer purchasing patterns. Specific seasonal trends in investor interest or funding are not publicly available.

Enveric Biosciences, Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Their lead product candidates include EB-003, a neuroplastogen; EB-002, a synthetic prodrug of psilocin; EVM301 Series, drug candidates for mental health disorders; EV104, a cannabinoid conjugate molecule for osteoarthritis; EVM-101 and EVM-201, cannabinoid medicines for cancer-related distress; and cannabinoid conjugate molecules for pain and cancer, along with a topical solution for radiodermatitis.

Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts, and maintains offices in Naples, Florida, and Calgary, Alberta, Canada.

Enveric Biosciences' brand reputation has been influenced by challenging stock performance and scientific advancements. The stock price decline and Nasdaq delisting notice negatively impacted its financial reputation, while patent issuances and positive updates on drug candidates like EB-003, EB-002, and the EVM301 series bolstered its scientific reputation. The after-hours stock surge following the EVM301 patent allowance indicates positive market reception to scientific milestones.

Enveric Biosciences, Inc. has 13.82% institutional ownership, with major holders including Advisorshares Investments Llc and UBS Group Ag. Top shareholders include TO Pharmaceuticals LLC / TOP Invest LLC (19.80%), Armistice Capital, LLC / Steven Boyd (9.99%), B. Asher / Capital LLC / P. Kopin (9.99%), AdvisorShares Trust (5.60%), and Hudson Bay Capital Management LP / Sander Gerber (5.04%). Frank Pasqualone purchased shares, while Joseph Tucker, Peter J. Facchini, and Kevin Michael Coveney sold shares.